Zobrazeno 1 - 10
of 244
pro vyhledávání: '"Peter A. LeWitt"'
Publikováno v:
Neurobiology of Disease, Vol 177, Iss , Pp 105962- (2023)
Background: Reliable and sensitive biomarkers are needed for enhancing and predicting Parkinson's disease (PD) diagnosis. Objective: To investigate comprehensive metabolomic profiling of biochemicals in CSF and serum for determining diagnostic biomar
Externí odkaz:
https://doaj.org/article/35679c3a473341e9856df3f891045a98
Autor:
Peter A. LeWitt, Fabrizio Stocchi, David Arkadir, Yoseph Caraco, Liat Adar, Itay Perlstein, Ryan Case, Nir Giladi
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
BackgroundWhile treatment with levodopa remains the cornerstone of Parkinson's disease (PD) management, chronic oral therapy is often associated with the development of motor complications, that correlate to fluctuating levodopa plasma concentrations
Externí odkaz:
https://doaj.org/article/2e0b3f45482d4711ba22562ad5a6604c
Autor:
Christos Sidiropoulos, Susan M. Bowyer, Andrew Zillgitt, Peter A. LeWitt, Hassan Bagher-Ebadian, Esmaeil Davoodi-Bojd, Jason M. Schwalb, Richard Rammo, Ellen Air, Hamid Soltanian-Zadeh
Publikováno v:
Case Reports in Neurological Medicine, Vol 2017 (2017)
Background. Dystonia is a syndrome with varied phenomenology but our understanding of its mechanisms is deficient. With neuroimaging techniques, such as fiber tractography (FT) and magnetoencephalography (MEG), pathway connectivity can be studied to
Externí odkaz:
https://doaj.org/article/2f58e2371ba644de8d54a19caf4aab1b
Autor:
Abhimanyu Mahajan, Andrew Zillgitt, Abdullah Alshammaa, Neepa Patel, Christos Sidiropoulos, Peter A. LeWitt, Susan Bowyer
Publikováno v:
Brain Sciences, Vol 8, Iss 9, p 159 (2018)
Background: Cervical dystonia (CD) patients have impaired working memory, processing speed and visual-motor integration ability. We used magnetoencephalography (MEG) to investigate changes in cerebral oscillations in CD patients during an executive f
Externí odkaz:
https://doaj.org/article/27956c8a4d7c43eaac36a03901d87bfa
Publikováno v:
Journal of Parkinson's Disease. :1-11
Patients with Parkinson’s disease often suffer from OFF symptoms disrupting their daily routines and adding to disabilities. Despite polypharmacy and adjustments to medication schedules, they often do not experience consistent relief from their mot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c291813e3b2decc96d232192b330d724
https://doi.org/10.3233/jpd-230055
https://doi.org/10.3233/jpd-230055
Publikováno v:
Journal of Neural Transmission. 130:821-826
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35e27ac3355727cba75d28fc5bb93fbd
https://doi.org/10.1007/s00702-023-02636-3
https://doi.org/10.1007/s00702-023-02636-3
Publikováno v:
Clinical Neuropharmacology. 46:66-78
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85437541e23d242cd975788eca094603
https://doi.org/10.1097/wnf.0000000000000540
https://doi.org/10.1097/wnf.0000000000000540
Publikováno v:
Journal of Parkinson's Disease. 11:2027-2034
Background: Hypokinetic dysarthria and dysphagia are known features of Parkinson’s disease; however, self-perception of their handicapping effects on emotional, physical, and functional aspects of quality of life over disease duration is less under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72079c734b018581f555f5a3e9c7514b
https://doi.org/10.3233/jpd-212621
https://doi.org/10.3233/jpd-212621
Publikováno v:
Expert Opinion on Drug Delivery. 18:1559-1569
Introduction: The most widely used pharmacological treatment for Parkinson’s disease is levodopa, the precursor for dopamine formation in the brain. Over time, the effectiveness of levodopa decline...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7cf9e6dbf340c62ac32550523fce8c4
https://doi.org/10.1080/17425247.2021.1960820
https://doi.org/10.1080/17425247.2021.1960820
Autor:
Nissim Sasson, Shir Fuchs Orenbach, Nir Giladi, Sheila Oren, David Arkadir, Tanya Simuni, Peter A. LeWitt, Abraham Zlotogorski, Alberto J. Espay, Werner Poewe, Astrid Thomas, Karl Kieburtz, Stuart Isaacson, Georg Ebersbach, Tami Yardeni, C Warren Olanow, Liat Adar, Ryan Case, Olivia Rosenfeld, Fabrizio Stocchi, Aaron Ellenbogen
Publikováno v:
Movement Disorders. 36:2687-2692
Background Continuous, subcutaneous (SC) levodopa/carbidopa infusion with ND0612 is under development as a treatment for patients with Parkinson's disease (PD) and motor fluctuations. Objective Evaluate 1-year safety data. Methods BeyoND is an open-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68a00bacc2997d5b31a70dc6f2f9c4e3
https://doi.org/10.1002/mds.28758
https://doi.org/10.1002/mds.28758